The estimated Net Worth of Milton H. Werner is at least 7.35 百万$ dollars as of 16 August 2022. Dr Werner owns over 5,000 units of Inhibikase Therapeutics stock worth over 7,042,772$ and over the last 4 years he sold IKT stock worth over 0$. In addition, he makes 307,341$ as CEO、 Pres & Director at Inhibikase Therapeutics.
Dr has made over 7 trades of the Inhibikase Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of IKT stock worth 4,000$ on 16 August 2022.
The largest trade he's ever made was exercising 43,707 units of Inhibikase Therapeutics stock on 14 May 2021 worth over 16,609$. On average, Dr trades about 11,909 units every 42 days since 2021. As of 16 August 2022 he still owns at least 5,335,433 units of Inhibikase Therapeutics stock.
You can see the complete history of Dr Werner stock trades at the bottom of the page.
Dr. Milton H. Werner is the CEO, Pres & Director at Inhibikase Therapeutics.
As the CEO、 Pres & Director of Inhibikase Therapeutics, the total compensation of Dr Werner at Inhibikase Therapeutics is 307,341$. There are no executives at Inhibikase Therapeutics getting paid more.
Dr Werner is 58, he's been the CEO、 Pres & Director of Inhibikase Therapeutics since . There are 1 older and no younger executives at Inhibikase Therapeutics. The oldest executive at Inhibikase Therapeutics, Inc. is Joseph Frattaroli CPA, 59, who is the Chief Financial Officer.
Milton's mailing address filed with the SEC is 3350 RIVERWOOD PARKWAY SE, SUITE 1900, , ATLANTA, GA, 30339.
Over the last 4 years, insiders at Inhibikase Therapeutics have traded over 0$ worth of Inhibikase Therapeutics stock and bought 47,537 units worth 63,897$ . The most active insiders traders include Milton H. Werner、Elizabeth G. O'farrell、Joseph Frattaroli. On average, Inhibikase Therapeutics executives and independent directors trade stock every 57 days with the average trade being worth of 22,267$. The most recent stock trade was executed by Milton H. Werner on 16 August 2022, trading 5,000 units of IKT stock currently worth 4,000$.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Inhibikase Therapeutics executives and other stock owners filed with the SEC include: